AveXis Inc. (AVXS) Stock Price Down 3.2%
AveXis Inc. (NASDAQ:AVXS)’s share price was down 3.2% on Tuesday . The company traded as low as $41.03 and last traded at $42.16, with a volume of 343,823 shares. The stock had previously closed at $43.57.
A number of equities analysts have weighed in on AVXS shares. Chardan Capital restated a “buy” rating and set a $60.00 price objective on shares of AveXis in a research report on Monday, May 9th. Jefferies Group cut shares of AveXis from a “buy” rating to a “hold” rating and upped their price objective for the stock from $39.00 to $42.00 in a research report on Wednesday, June 22nd. They noted that the move was a valuation call. Wells Fargo & Co. started coverage on shares of AveXis in a research report on Friday, July 15th. They set a “market perform” rating for the company. Goldman Sachs Group Inc. upped their price objective on shares of AveXis from $28.00 to $47.00 and gave the stock a “buy” rating in a research report on Friday, May 13th. Finally, Zacks Investment Research cut shares of AveXis from a “hold” rating to a “sell” rating in a research report on Wednesday, June 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $45.40.
The company’s 50 day moving average price is $37.08 and its 200 day moving average price is $31.48. The firm’s market capitalization is $958.06 million.
AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, August 11th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.09. On average, equities analysts anticipate that AveXis Inc. will post ($3.64) EPS for the current fiscal year.
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.